Preparation methods for palbociclib free base crystal form A and crystal form B

Patent metadata

Field	Value
Publication number	US-10766895-B2
Application number	US-201916405722-A
Country	US
Kind code	B2
Filing date	May 7, 2019
Priority date	Nov 2, 2015
Publication date	Sep 8, 2020
Grant date	Sep 8, 2020

Abstract

Disclosed is a preparation method for a Palbociclib free base crystal form A as shown in Formula I, comprising the following steps: treating a Palbociclib free base and/or a Palbociclib salt compound by using an inorganic base in a water solvent at the temperature of 35 to 100′C. to obtain a Palbociclib free base crystal form A, the water solvent being water or mixed solvent obtained by water and an organic solvent capable of being mixed and disclosed in the water. Also disclosed is a preparation method for a Palbociclib free base crystal form B, comprising the following steps: treating a Palbociclib salt compound by using an inorganic base in a water solvent at the temperature of 0 to 20° C. to obtain a Palbociclib free crystal form B, the water solvent being water or a mixed solvent obtained by water and an organic solvent capable of being mixed and dissolved in the water. The method is safe and convenient in operation and low in pollution, and facilitates industrial production.

First claim

The invention claimed is:

1. A method for preparing crystal form B of palbociclib of the Formula I: the method comprising:

treating a pharmaceutically acceptable salt of palbociclib with a base selected from the group consisting of ammonia, sodium hydroxide, potassium hydroxide, sodium carbonate and potassium carbonate in an aqueous solvent selected from the group consisting of water and a co-solvent mixture consisting of water and a water-miscible organic solvent selected from the group consisting of methanol, ethanol, isopropanol and tetrahydrofuran, at a temperature in the range of 0° C. to 20° C., to obtain crystal form B of palbociclib;
wherein crystal form B of palbociclib exhibits an X-ray powder diffraction pattern comprising characteristic peaks having 2θ angles selected from the group consisting of 6.094°, 6.692°, 11.049°, 12.154°, 12.940°, 16.498°, 19.879°, 22.684°, and 26.778°.

2. The method according to claim 1 , wherein the pharmaceutically acceptable salt of palbociclib is selected from the group consisting of palbociclib isethionate, palbocklib hydrochloride, palbociclib sulfate, and palbociclib methane sulfonate or a combination thereof.

3. The method according to claim 1 , wherein the inorganic base is selected from the group consisting of sodium hydroxide, potassium hydroxide, sodium carbonate, and potassium carbonate.

4. The method according to claim 1 , wherein the water-miscible organic solvent is selected from the group consisting of methanol, ethanol and isopropanol.

5. The method according to claim 1 , wherein the volume ratio of water and the water-miscible organic solvent in the aqueous solvent is 1:0 to 1:20.

6. The method according to claim 1 , wherein the volume ratio of water and the water-miscible organic solvent in the aqueous solvent is 1:0 to 1:2.

7. The method according to claim 1 , wherein the treatment is performed at a pH greater than 8.0.

8. The method according to claim 1 , wherein the treatment is performed at a pH greater than 10.0.

9. The method according to claim 1 , wherein the treatment is performed at a temperature in the range of 5 ° C. to 15 ° C.

Assignees

• Zhejiang Huahai Pharm Co Ltd
• Shanghai Syncores Tech Inc Ltd

Inventors

• Fan Haisheng
• Guo Xiaowen
• Huang Luning
• Gu Hong

Classifications

• A61K31/519

  ortho- or peri-condensed with heterocyclic rings · CPC title

• B01D9/0054

  Use of anti-solvent · CPC title

• C07D471/04 Primary

  Ortho-condensed systems · CPC title

• B01D9/0063

  Control or regulation (control per se G05) · CPC title

• A61P35/00

  Antineoplastic agents · CPC title